These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24799524)

  • 1. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
    Matas-Céspedes A; Rodriguez V; Kalko SG; Vidal-Crespo A; Rosich L; Casserras T; Balsas P; Villamor N; Giné E; Campo E; Roué G; López-Guillermo A; Colomer D; Pérez-Galán P
    Clin Cancer Res; 2014 Jul; 20(13):3458-71. PubMed ID: 24799524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
    Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
    Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.
    Lee CG; Das B; Lin TL; Grimes C; Zhang X; Lavezzi T; Huang L; Cole J; Yau L; Li L
    Br J Haematol; 2012 Jul; 158(1):79-90. PubMed ID: 22509798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
    Blanco B; Herrero-Sánchez C; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
    Int Immunopharmacol; 2015 Sep; 28(1):675-85. PubMed ID: 26256696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model.
    Qin G; Chen Y; Li H; Xu S; Li Y; Sun J; Rao W; Chen C; Du M; He K; Ye Y
    Mol Med Rep; 2016 Jul; 14(1):57-68. PubMed ID: 27177128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome.
    Jin MK; Hoster E; Dreyling M; Unterhalt M; Hiddemann W; Klapper W
    Histopathology; 2011 Mar; 58(4):586-92. PubMed ID: 21401698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connexin 43 communication channels in follicular dendritic cell development and in follicular lymphomas.
    Rajnai H; Teleki I; Kiszner G; Meggyesházi N; Balla P; Vancsik T; Muzes G; Csomor J; Matolcsy A; Krenacs T
    J Immunol Res; 2015; 2015():528098. PubMed ID: 25815348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
    PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
    J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.
    Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S
    Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
    Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
    Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
    Valero JG; Matas-Céspedes A; Arenas F; Rodriguez V; Carreras J; Serrat N; Guerrero-Hernández M; Yahiaoui A; Balagué O; Martin S; Capdevila C; Hernández L; Magnano L; Rivas-Delgado A; Tannheimer S; Cid MC; Campo E; López-Guillermo A; Colomer D; Pérez-Galán P
    Leukemia; 2021 Sep; 35(9):2635-2649. PubMed ID: 33731849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.
    Zhao P; Hall J; Durston M; Voydanoff A; VanSickle E; Kelly S; Nagulapally AB; Bond J; Saulnier Sholler G
    PLoS One; 2017; 12(6):e0179948. PubMed ID: 28662162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
    Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
    Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
    Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
    Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
    Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.